KEYNOTE-F58 (MK-3475-F58)
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- NCT05482893 ↗
- Recruiting
- Phanes Therapeutics
- Focused
We haven't built an HCP commentary report on KEYNOTE-F58 (MK-3475-F58) (spevatamig, abraxane and 10 more in Gastric or Gastroesophageal Junction Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KEYNOTE-F58 (MK-3475-F58) so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancer (BTC); Colorectal Cancer
- Interventions
- Spevatamig (PT886); Paclitaxel; Gemcitabine; Abraxane; KEYTRUDA® (pembrolizumab); FOLFOX; CAPOX; FOLFIRINOX; TAS 102; Bevacizumab; Gemcitabine Combined With Cisplatin; NALIRIFOX
- Arms
- Dose Escalation · Experimental
- Dose Expansion · Experimental
- Combination Expansion with Chemotherapy or Targeted Therapy · Experimental
- Combination Expansion with KEYTRUDA® (pembrolizumab) · Experimental
- Enrollment
- 350 (estimated)
- Primary outcomes
- To evaluate the safety and tolerability of Spevatamig (PT886) as monotherapy and in each individual combination substudy.
- To evaluate anti-tumor activity of PT886 as assessed by ORR, in Spevatamig (PT886) monotherapy and in each combination substudy.
- To determine the recommended dose for expansion of Spevatamig (PT886) monotherapy.
- Sponsor
- Phanes Therapeutics with Merck Sharp & Dohme LLC
- Start
- Mar 15, 2023
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05482893 · updated Sep 28, 2026